Patentable subject matter in the United States is governed by 35 U.S.C. 101. The current patentable subject matter practice in the U.S. is very different from the corresponding practices by WIPO/Patent Cooperation Treaty, and it is considered to be broader in general. Since the enactment of the subject matter requirement ca. 1970, the interpretation of the statute changed multiple times. Although Section 101 of Title 35 U.S.C. reads:
and, thus, does not say what is patent-eligible and what is not, US courts felt that some inventions should not be subjected to patent monopoly at all (supposedly because certain claims may be too broad and may pre-empt all uses of a particular discovery), and used U.S.C. 101 as an excuse to enforce their own believes (and not of the US Congress). To quote the SCOTUS in Myriad: "Without this exception, there would be considerable danger that the grant of patents would ‘tie up’ the use of such tools and thereby ‘inhibit future innovation premised upon them.’"
The two particularly contentious areas, with numerous reversals of prior legislative and judicial decisions, have been computer-based (see Software patents under United States patent law) and biological inventions. While these two areas present different types of challenges:
(a) the problem with biological inventions is where the discovery of Nature's work ends and where a human invention begins, i.e. patent monopoly should not encompass a "natural phenomenon or a law of nature".
(b) the problem with the software inventions (such as “mathematical algorithms, including those executed on a generic computer,... [and] some fundamental economic and conventional business practices") is that the scope of such claims is incommensurably broad compared to their contribution to "the Progress of Science" (quid pro quo),
the US Courts rejected early attempts to develop different set of rules for the two challenges and instead tried to find a common approach to these, as well to potential other subject matter eligibility challenges in the future. One amicus curiae plainly called this approach "one attempt [at] a universal framework via amorphous and misguided patent eligibility requirements."
Nevertheless, this approach, known as Alice-
Mayo framework, was developed by the SCOTUS in 2012–2014, and has been used by the USPTO and by US courts since. The unified Alice-Mayo approach to subject matter eligibility requires (1) the newly discovered Law of Nature or mathematical formula to be assumed as known, (2) an additional "inventive concept", that limits the application of (1) to a specific and non-trivial use.
There is an important relationship between patent eligibility and non-obviousness tests in the US patent law. The non-obviousness criterion can be easily met, if a claim is based on a discovery of new natural phenomenon/principle/law. In the patentable subject matter analysis, however, this "discovery" is assumed to be prior art, and an "additional inventive concept" must be present in the claim.
Although the details are discussed below, the net result as of year 2023 can be summarized as follows:
Things (including living organisms and nucleic acids) found in nature are not patent-eligible (Funk Bros. Seed Co. v. Kalo Inoculant Co.) even, when isolated from their natural environment (e.g. a protein-encoding gene from a chromosome), but things (even alive) "made by man" may be (Diamond v. Chakrabarty, Association for Molecular Pathology v. Myriad Genetics, Inc.), provided that they are different in a useful manner from their natural predecessor(s).
In the case of computer-implemented methods, the algorithms (even new and non-obvious) per se are not patentable (Gottschalk v. Benson, Parker v. Flook), and an additional "inventive concept" is required to limit the algorithm to new and useful application(s) (Diamond v. Diehr).